Related Experiment Video
Updated: Jan 28, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid
Hsin-Chia Liao1, Yi-Ju Chou2, Ching-Cheng Lin1
1Institute of Traditional Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
Abstract:
Chronic myelogenous leukemia (CML) is clinically treated with imatinib, which inhibits the kinase activity of the Bcr-Abl oncoprotein. However, imatinib resistance remains a common clinical issue. Andrographolide, the major compound of the medicinal plant Andrographis paniculata, was reported to exhibit anticancer activity. In this study, we explored the therapeutic potential of andrographolide and its derivative, NCTU-322, against both imatinib-sensitive and imatinib-resistant human CML cell lines. Both andrographolide and NCTU-322 downregulated the Bcr-Abl oncoprotein in imatinib-resistant CML cells through an Hsp90-dependent mechanism similar to that observed in imatinib-sensitive CML cells. In addition, NCTU-322 had stronger effects than andrographolide on downregulation of Bcr-Abl oncoprotein, induction of Hsp90 cleavage and cytotoxicity of CML cells. Notably, andrographolide and NCTU-322 could induce differentiation, mitotic arrest and apoptosis of both imatinib-sensitive and imatinib-resistant CML cells. Finally, the anticancer activity of NCTU-322 against imatinib-resistant CML cells was demonstrated in vivo. In summary, our data demonstrated that andrographolide and NCTU-322 inhibit Bcr-abl function via a mechanism different from that of imatinib, and they induced multiple anticancer effects in both imatinib-sensitive and resistant CML cells. Our findings demonstrate that andrographolide and NCTU-322 are potential therapeutic agents again CML.
Insights
Andrographolide and NCTU-322 show promise for treating chronic myelogenous leukemia (CML). These compounds target the Bcr-Abl oncoprotein in both imatinib-sensitive and resistant CML cells, offering a new therapeutic avenue.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is primarily treated with imatinib, targeting the Bcr-Abl oncoprotein.
- Imatinib resistance is a significant clinical challenge in CML treatment.
- Andrographolide, from Andrographis paniculata, exhibits known anticancer properties.
Purpose of the Study:
- To investigate the therapeutic potential of andrographolide and its derivative NCTU-322 against imatinib-sensitive and resistant CML.
- To elucidate the mechanism of action of andrographolide and NCTU-322 in CML cells.
Main Methods:
- Treatment of human CML cell lines (imatinib-sensitive and resistant) with andrographolide and NCTU-322.
- Analysis of Bcr-Abl oncoprotein levels and Hsp90-dependent mechanisms.
- Assessment of cytotoxicity, differentiation, mitotic arrest, and apoptosis induction.
- In vivo studies to evaluate anticancer activity in imatinib-resistant CML models.
Main Results:
- Both andrographolide and NCTU-322 downregulated Bcr-Abl in resistant CML cells via an Hsp90-dependent pathway.
- NCTU-322 demonstrated superior efficacy over andrographolide in Bcr-Abl downregulation, Hsp90 cleavage, and cytotoxicity.
- Both compounds induced differentiation, mitotic arrest, and apoptosis in sensitive and resistant CML cells.
- NCTU-322 exhibited significant in vivo anticancer activity against imatinib-resistant CML.
Conclusions:
- Andrographolide and NCTU-322 inhibit Bcr-Abl function through a distinct mechanism compared to imatinib.
- These compounds induce multiple anticancer effects, including differentiation, mitotic arrest, and apoptosis.
- Andrographolide and NCTU-322 represent potential therapeutic agents for both imatinib-sensitive and resistant CML.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Differentiation of Common Myeloid Progenitor Cells
Directing and Steric Effects in Disubstituted Benzene Derivatives
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Resistivity
Resistance

